Stay updated on Lazertinib vs Intravenous Amivantamab in Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Lazertinib vs Intravenous Amivantamab in Lung Cancer Clinical Trial page.

Latest updates to the Lazertinib vs Intravenous Amivantamab in Lung Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedRevision v3.4.2 was added and revision v3.4.1 was removed.SummaryDifference0.0%

- Check18 days agoChange DetectedPosted results data for the PALOMA-3 study, including Ctrough and AUC Day 1-15 PK endpoints for Cycle 2 Day 1 and Cycle 4 Day 1, with regional notes and timing details. Deleted several earlier results metrics definitions that were previously shown.SummaryDifference2%

- Check32 days agoChange DetectedThe changes update and standardize metadata display (glossary toggle, last update fields, FEAR Act labeling, and revision version) with some capitalization adjustments. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check39 days agoChange DetectedResults Submitted replaces No Results Posted on the study page, and the revision note updates to v3.3.4. This indicates that results for the study have been submitted.SummaryDifference0.0%

- Check60 days agoChange DetectedThe Study Details page now displays 'Last Update Posted (Estimated)' instead of 'Last Update Posted', indicating that the update time may be approximate. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check67 days agoChange DetectedThe Locations section now includes new entries across California, Colorado, Florida, Kansas, Michigan, New Jersey, New York, Oregon, Pennsylvania, South Carolina, Virginia, and Ontario. Some previously listed location sections were removed.SummaryDifference0.6%

Stay in the know with updates to Lazertinib vs Intravenous Amivantamab in Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lazertinib vs Intravenous Amivantamab in Lung Cancer Clinical Trial page.